Raiff Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Raiff Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-43,000	Closed	-$2.68M	–	50
2015 Q1	$2.68M	Buy	+43,000	New	+$2.5M	2.51%	15

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Raiff Partners's TEVA Position: Q2 2015 in Review

Raiff Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 43,000 shares — an estimated $2.68M sold.

Raiff Partners first reported a position in TEVA in Q1 2015 and held it in 1 quarter. The position peaked at $2.68M in Q1 2015. 818 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

Raiff Partners reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Raiff Partners sold 43,000 Teva Pharmaceuticals shares in Q2 2015, an estimated $2.68M.
Raiff Partners first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 1 quarter.
Raiff Partners's Teva Pharmaceuticals position peaked at $2.68M in Q1 2015.
818 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on Raiff Partners's 13F filing for Q2 2015, filed 13 Aug 2015.